Theralase Technologies Inc. V.TLT

An example of deceptive headlines for Adstiladrin

[DJDawg]

https://www.medpagetoday.com/meetingcoverage/suo/107650

The headline is

First Gene Therapy for Non-Muscle-Invasive Bladder Cancer Offers Durable Response

— A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years

Whereas what it should read is a quarter of those who responded AT ALL were recurrence free at 3 years.

Or it could read

12% of those initialy treated were recurrence free at 3 years.

[Eoganacht]

Yes - very deceptive. And this kind of thing is done a lot. If Theralase were to play that game and we end up with a 35% CRR at 3 years, our headline might read: More than one half of Theralase patients with high-risk BCG-unresponsive disease were recurrence free at 3 years

[StevenBirch]

Well let's hope the FDA sees through deceptive headlines like that, I'm sure they do just like I'm sure Roger knows they do. Doesn't TLT really have the trifecta - better CR numbers, fewer AE's and fewer/less invasive treatments than the competition? I'm going to assume that all companies in this field go through the same machinations and frustrations that we are going

[Paradise818]

I seriously doubt the FDA will see anything.  They are controlled by BIG pharma period.

[DeathXray33]

Asstilladrin (a mess). Merc made a messtake... They shall soon see...